Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Oxaliplatin neurotoxicity].

Laurence Gamelin1, Michèle Boisdron-Celle, Alain Morel

  • 1Service de toxicologie, Centre Antipoisons, CHU Angers, Angers.

Bulletin Du Cancer
|February 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Technical recommendations from a large-scale French Delphi consensus: A step toward European harmonization of ctDNA analysis.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Thymine as potential biomarker to predict 5-FU systemic exposure in patients with gastro-intestinal cancer: a prospective pharmacokinetic study (FUUT-trial).

Cancer chemotherapy and pharmacology·2025
Same author

Learning to Train and to Explain a Deep Survival Model with Large-Scale Ovarian Cancer Transcriptomic Data.

Biomedicines·2025
Same author

T-cell-related skin inflammatory flareups with Th1 polarity in a patient with pseudoxanthoma elasticum.

Skin health and disease·2024
Same author

A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024

Oxaliplatin causes frequent, potentially irreversible neurotoxicity in digestive cancer patients. Calcium-magnesium infusion shows promise for preventing this severe side effect.

Area of Science:

  • Oncology
  • Neuroscience
  • Pharmacology

Background:

  • Oxaliplatin is a key chemotherapy drug for digestive tract tumors, particularly colorectal cancer.
  • A significant dose-limiting toxicity of oxaliplatin is peripheral sensory neuropathy, affecting up to 80% of patients.
  • This neuropathy can be acute and transient or progress to chronic, irreversible sensory loss and functional impairment.

Purpose of the Study:

  • To review the mechanisms of oxaliplatin-induced neurotoxicity.
  • To evaluate various strategies for preventing or mitigating this adverse effect.
  • To highlight promising preventive approaches for clinical consideration.

Main Methods:

  • Review of existing literature on oxaliplatin neurotoxicity mechanisms and prevention strategies.

Related Experiment Videos

  • Analysis of different classes of agents investigated for neuroprotection, including channel modulators, antioxidants, and neurotrophic factors.
  • Assessment of the efficacy and safety data for proposed interventions.

    • Main Results:

    • Oxaliplatin neurotoxicity stems from increased neuronal excitability via voltage-gated sodium channel interaction, mediated by calcium chelation.
    • Numerous preventive strategies have been explored, including modified dosing, sodium channel blockers, antioxidants, and neurotrophic agents.
    • Calcium-magnesium infusion emerged as a potentially efficient and safe approach in preliminary evaluations.

    Conclusions:

    • Oxaliplatin-induced neurotoxicity is a common and serious concern in cancer treatment.
    • Understanding the underlying mechanisms is crucial for developing effective preventive measures.
    • Calcium-magnesium infusion warrants further investigation as a viable strategy to manage oxaliplatin neurotoxicity.